Senior Manager / Associate Director, Accounting & Finance - Acrivon Therapeutics

Acrivon is a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing Acrivon’s proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics, or AP3. The AP3 platform is engineered to measure compound-specific effects on the entire tumor cell protein signaling network and drug-induced resistance mechanisms in an unbiased manner. These distinctive capabilities enable AP3’s direct application for drug design optimization for monotherapy activity, the identification of rational drug combinations, and the creation of drug-specific proprietary OncoSignature companion diagnostics that are used to identify the patients most likely to benefit from Acrivon’s drug candidates. Acrivon is currently advancing its lead candidate, ACR-368 (also known as prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial across multiple tumor types. The company has received Fast Track designation from the Food and Drug Administration, or FDA, for the investigation of ACR-368 as monotherapy based on OncoSignature-predicted sensitivity in patients with platinum-resistant ovarian or endometrial cancer. Acrivon’s ACR-368 OncoSignature test, which has not yet obtained regulatory approval, has been extensively evaluated in preclinical studies, including in two separate, blinded, prospectively-designed studies on pretreatment tumor biopsies collected from past third-party Phase 2 trials in patients with ovarian cancer treated with ACR-368. The FDA has granted Breakthrough Device designation for the ACR-368 OncoSignature assay for the identification of ovarian cancer patients who may benefit from ACR-368 treatment. The company reported positive clinical data for ovarian and endometrial cancers in April 2024, and in September 2024 it reported additional positive clinical data for endometrial cancer, including a confirmed overall response rate of 62.5% (95% C.I. 30.4% - 86.5%) and further validation of its prospective OncoSignature selection of patients predicted sensitive to ACR-368 by showing segregation of responders in OncoSignature-positive versus OncoSignature-negative patients (p = 0.009). The median duration of treatment was not yet reached, but the duration on study was 6 months at the time of the data cut.

In addition to ACR-368, Acrivon is also leveraging its proprietary AP3 precision medicine platform for developing its co-crystallography-driven, internally-discovered pipeline programs. These include ACR-2316, the company’s second clinical stage asset, a potent, selective WEE1/PKMYT1 inhibitor designed for superior single-agent activity as demonstrated in preclinical studies against benchmark inhibitors. The company is also progressing internally- developed preclinical programs, including a cell cycle program with an undisclosed target.

Acrivon has developed AP3 Interactome, a proprietary, computational analytics platform driven by machine learning for integrated comprehensive analyses across all large, in-house AP3 phosphoproteomic drug profiling data sets to advance its in-house research programs.

Our global team operates out of two leading life science clusters, Watertown, MA and Medicon Village in Lund, Sweden.

Position Overview:

Come help Acrivon save lives and innovate precision medicine. The Senior Manager/Associate Director, Accounting and Finance  will be a key team member supporting the company leadership across multiple functions.  This individual will leverage strong experience in public accounting to support accounting and reporting requirements, while also building out the internal business partner function and expand their own exposure and knowledge across the biotech industry. This position will be based in Watertown, MA.

The ideal candidate will be a collaborative, enthusiastic team member with high leadership potential and a willingness to learn and be exposed to new areas of the business.  They will have a strong background in public company requirements to support the continued scaling of accounting operations, while at the same time will work with directly with the leadership team to build out a business partner function and eventually lead the departmental budgeting and internal reporting components.  This highly-visible role will be an integral part of the existing Accounting team, while also will learn about, participate in, and eventually lead the many aspects of Financial Planning & Analysis.  This individual will partner with key stakeholders across the executive team, and organization as a whole, with emphasis on solidifying our public company obligations and increasing transparency and efficiencies with the forecast, and managing budget and forecast accuracy.  This individual will be a contributor across the accounting, finance, and broader organization in leading and supporting initiatives to build a scalable multi-product biotech. 

Duties and Responsibilities:

Primary job duties and responsibilities will include:

• With Accounting team, support financial statement close processes
  • Strong understanding of US GAAP, accounting, financial reporting, and internal controls supporting overall operations as a public company
  • Ownership of clinical trial and equity routine procedures
• Business Partner across functions to develop strong financial management and analytical support
  • Support function and program analysis, business development, and financial scenario planning
  • Build routine easily-digestible internal reports for department and program leads and company leadership
• Lead efforts in implementing the latest systems and tools for managing the financial forecast and internal management reporting
  • Increase visibility of financial information (past and future)
  • Create dashboards for easily digestible and re-creatable financial information
• Support broader organization through ad hoc projects and analysis as needed

Requirements and Qualifications:

• Bachelors degree, and 5+ years of public company audit experience at a Big 4 Accounting Firm or mix of public audit and industry
• Demonstrated strong collaborative and analytical skills
• Proven experience in willingness to learn and eventually own new skillsets
• Excellent written and oral communication skills
• Comfortable managing multiple priorities simultaneously
• CPA a strong plus
• Demonstrated leadership potential a strong plus
• Auditor or industry-based biotech experience a strong plus

Acrivon Therapeutics is proud to be an equal opportunity employer and to provide equal opportunities to all employees and applicants for employment without regard to race, color, religion, sex or gender identity, national origin, age, disability, sexual orientation or genetics. In addition to federal law requirements, Acrivon Therapeutics complies with applicable state and local laws governing nondiscrimination in employment.